When did SANGAMO THERAPEUTICS INC (SGMO) report earnings last quarter?
SANGAMO THERAPEUTICS INC (SGMO) last reported earnings on 11/6/2025.
NASDAQ:SGMO • US8006771062
Past quarterly earnings results for SANGAMO THERAPEUTICS INC (SGMO), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.11 | 0.00 | -63,537.14% | -375.00% | 581K | 35.088M | -98.34% | -98.82% |
| Q2 2025 | -0.08 | -0.13 | 38.49% | 55.56% | 18.306M | 32.314M | -43.35% | 5,042.13% |
| Q1 2025 | -0.14 | -0.13 | -5.04% | 48.15% | 6.437M | 7.565M | -14.91% | 1,238.25% |
| Q4 2024 | -0.11 | -0.09 | -18.18% | 67.65% | 7.551M | 13.889M | -45.63% | 269.78% |
| Q3 2024 | 0.04 | -0.03 | 237.26% | 106.78% | 49.412M | 18.302M | 169.98% | 425.77% |
| Q2 2024 | -0.18 | -0.15 | -21.11% | 72.73% | 356K | 8.425M | -95.77% | -94.79% |
| Q1 2024 | -0.27 | -0.22 | -23.84% | -325.00% | 481K | 6.788M | -92.91% | -99.70% |
| Q4 2023 | -0.34 | -0.26 | -30.10% | -6.25% | 2.042M | 8.267M | -75.30% | -92.49% |
| Q3 2023 | -0.59 | -0.33 | -80.76% | -73.53% | 9.398M | 10.613M | -11.45% | -64.54% |
| Q2 2023 | -0.66 | -0.35 | -88.94% | -127.59% | 6.835M | 15.129M | -54.82% | -76.75% |
| Q1 2023 | 0.12 | -0.33 | 135.85% | 140.00% | 157.957M | 24.546M | 543.51% | 460.13% |
| Q4 2022 | -0.32 | -0.37 | 12.85% | -23.08% | 27.2M | 27.394M | -0.71% | -2.86% |
| Q3 2022 | -0.34 | -0.36 | 6.22% | -3.03% | 26.5M | 27.321M | -3.01% | -7.34% |
| Q2 2022 | -0.29 | -0.36 | 19.40% | 12.12% | 29.4M | 25.123M | 17.02% | 5.38% |
| Q1 2022 | -0.30 | -0.32 | 5.43% | 6.25% | 28.2M | 27.831M | 1.33% | 7.22% |
| Q4 2021 | -0.26 | -0.35 | 26.21% | 10.34% | 28M | 27.36M | 2.34% | 8.53% |
| Q3 2021 | -0.33 | -0.34 | 4.00% | -3,200.00% | 28.6M | 25.693M | 11.31% | -50.52% |
| Q2 2021 | -0.33 | -0.32 | -3.45% | -26.92% | 27.9M | 27.014M | 3.28% | 29.17% |
| Q1 2021 | -0.32 | -0.30 | -6.84% | 13.51% | 26.3M | 25.146M | 4.59% | 100.76% |
| Q4 2020 | -0.29 | -0.22 | -33.65% | - | 25.8M | 32.795M | -21.33% | - |
| Q3 2020 | -0.01 | -0.25 | 95.95% | - | 57.8M | 27.08M | 113.44% | - |
| Q2 2020 | -0.26 | 0.07 | -464.15% | - | 21.6M | 104.76M | -79.38% | - |
| Q1 2020 | -0.37 | -0.29 | -26.67% | - | 13.1M | 23.191M | -43.51% | - |
Notes
SANGAMO THERAPEUTICS INC (SGMO) last reported earnings on 11/6/2025.
SANGAMO THERAPEUTICS INC (SGMO) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, SANGAMO THERAPEUTICS INC (SGMO) has beaten EPS estimates in 1 out of 4 releases.